Recent clinical trials in patients with inflammatory diseases like multiple sclerosis (MS) or inflammatory bowel disease (IBD) have shown the beneficial effects of probiotic helminth administration, although the underlying mechanism of action remains largely unknown. Potential cellular targets may include innate immune cells that propagate inflammation in these diseases, like proinflammatory macrophages. We here investigated the effects of the helminth Trichuris suis soluble products (SPs) on the phenotype and function of human inflammatory (granulocyte-macrophage colony-stimulating factor (GM-CSF)-differentiated) macrophages. Interestingly, we here show that T. suis SPs potently skew inflammatory macrophages into a more anti-inflammatory state in a Tolllike receptor 4 (TLR4)-dependent manner, and less effects are seen when stimulating macrophages with TLR2 or -3 ligands. Gene microarray analysis of GM-CSF-differentiated macrophages further revealed that many TLR4-induced inflammatory mediators, including interleukin (IL)-12B, CCL1 and CXCL9, are downregulated by T. suis SPs. In particular, we observed a strong reduction in the expression and function of P2RX7, a purinergic receptor involved in macrophage inflammation, leading to reduced IL-1b secretion. In conclusion, we show that T. suis SPs suppress a broad range of inflammatory pathways in GM-CSF-differentiated macrophages in a TLR4-dependent manner, thereby providing enhanced mechanistic insight into the therapeutic potential of this helminth for patients with inflammatory diseases.
INTRODUCTION
In recent decades, the incidence and prevalence of chronic inflammatory diseases, including multiple sclerosis (MS), inflammatory bowel disease (IBD) and type I diabetes, have seen a marked increase, particularly in developed countries. 1 This regional increase is not explained by genetic factors or improved diagnostics, 2 making it evident that environmental factors are involved. A possible explanation for the increased incidence of autoimmune diseases is presented in the hygiene hypothesis. 1, 2 According to this hypothesis, a high level of hygiene in developed countries has led to low exposure to common pathogens, including helminths, causing a dysfunctional immune regulation in susceptible individuals as seen in allergies and autoimmune diseases. [3] [4] [5] Many epidemiological studies, as well as experiments in animal models and small-scale clinical trials, have shown that helminths can confer protection from several immune dysregulatory diseases, including MS and IBD. 1, 4, 5 In contrast, clinical trials in patients with allergic rhinitis or asthma using the helminth infection model did not result in suppression of disease activity, 6, 7 indicating that research that defines underlying mechanisms of helminth-induced immune modulation in different diseases is warranted.
Thus far, the treatment of MS patients with ova of the helminth Trichuris suis has shown positive results. In an observational study in MS patients, it was demonstrated that helminth-infected patients showed significantly fewer relapses, less magnetic resonance imaging activity and lower disability scores compared with uninfected patients. 8 Anthelmintic treatment in these helminth-infected patients led to a significant increase of radiological and clinical MS activity. 9 In a phase 1 clinical trial, five newly diagnosed MS patients were treated with T. suis ova. This study showed no adverse events and favorable trends were seen in magnetic resonance imaging and immunological assessments. 10 Moreover, in experimental autoimmune encephalomyelitis, a murine animal model for MS, we have recently shown that Trichuris suis soluble products (SPs) reduce the clinical symptoms, 11 together illustrating the therapeutic potential of helminths or their products for inflammatory diseases like MS.
Macrophages act as a first line of defense in the innate immune system and are specifically well equipped for maintaining homeostasis within the interstitial environment by elimination of cell debris and pathogens that are recognized via specific patternrecognition receptors such as Toll-like receptors (TLRs) and C-type lectin receptors. Upon TLR triggering, macrophages will produce a plethora of pro-inflammatory mediators, including tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b). 12 These innate immune cells can be divided into different subpopulations, based on their anatomical location and functional phenotype. The polar ends of these phenotypes are pro-inflammatory, classically activated macrophages at one extreme and regenerating, alternatively activated macrophages at the other extreme. Although this simplified depiction has its limitations, it clearly shows the heterogeneity of the macrophages in the human body. 13 It has been suggested that helminths induce protection from inflammatory diseases via the induction of alternatively activated macrophages.
14 In several murine IBD models, it was shown that injection of helminth-activated macrophages was sufficient to protect animals from disease.
14 In MS, macrophages play a dual role, as classically activated macrophages are suggested to contribute to lesion formation, whereas alternatively activated macrophages are thought to support lesion repair mechanisms. 15 Dendritic cells (DCs) and macrophages are closely related antigen-presenting cells, designed for uptake and presentation of antigens to leukocytes. 12 We have shown previously that T. suis SPs suppress the production of pro-inflammatory mediators in TLRactivated DCs, including IL-12, IL-6, TNF-a and CXCL9, 11, 16 but to date, the effect of T. suis on human macrophages is unknown. Therefore, we here investigated the effect of T. suis SPs on lipopolysaccharide (LPS)-induced inflammation in different types of human monocyte-derived macrophages, and in particular granulocyte-macrophage colony-stimulating factor (GM-CSF)-differentiated macrophages that can be regarded as classically activated macrophages. 17 This inflammatory cytokine has a crucial pathogenic role in neuroinflammation 18 that is further illustrated by the observation that GM-CSF-deficient mice are resistant to experimental autoimmune encephalomyelitis. 19 We here show that T. suis SPs induce significant changes in the transcriptome of GM-CSF-differentiated macrophages. In the presence of LPS, T. suis SPs suppress the LPS-induced pro-inflammatory signature, resulting in reduced mRNA expression of many pro-inflammatory mediators including cytokines, chemokines and transcription factors and a reduced secretion of pro-inflammatory cytokines such as IL-6 and TNF-a. Moreover, T. suis SPs are able to downregulate the expression of P2RX7, a purinergic receptor involved in macrophage inflammation, leading to reduced IL-1b secretion upon adenosine triphosphate (ATP) stimulation. In conclusion, our data indicate that T. suis SPs strongly reduce TLR4-induced proinflammatory properties of macrophages that may contribute to the protective effects of T. suis in various inflammatory diseases.
RESULTS

T. suis SPs modulate cytokine secretion in human macrophages
Monocytes were differentiated into pro-inflammatory macrophages (using GM-CSF), anti-inflammatory macrophages (using macrophage colony-stimulating factor (M-CSF)) or 'naive' macrophages (using normal human serum (NHS)) and were subsequently stimulated for 24 h with 100 ng ml À 1 of LPS in the presence or absence of T. suis SPs (40 or 80 mg ml À 1 ). Upon addition of a concentration of 40 mg ml À 1 T. suis SPs, LPS-induced TNF-a secretion was completely suppressed to background levels in all three macrophage subtypes, with the largest significant reduction in GM-CSF-differentiated macrophages (Figure 1 ). To establish the effects of T. suis SPs on these GM-CSF-differentiated macrophages in more detail, we performed gene microarray analysis (see below) and analysed cell supernatants to determine cytokine levels. The LPS-induced secretion of the pro-inflammatory mediators TNF-a (Figure 2a ) and IL-6 ( Figure 2b) were significantly reduced by T. suis SPs. In addition, the secretion of the anti-inflammatory cytokine IL-10 was significantly enhanced by T. suis SPs in the presence of LPS compared with LPS alone (Figure 2c ). In summary, T. suis SPs dampen the LPS-induced pro-inflammatory cytokine profile in GM-CSF-differentiated macrophages.
T. suis SPs alter gene expression in LPS-treated GM-CSFdifferentiated macrophages GM-CSF-differentiated macrophages co-incubated with T. suis SPs and LPS showed a total of 489 differentially expressed genes (Po0.05) compared with macrophages incubated with LPS alone. Out of 489 significantly altered genes, 249 were downregulated and 240 were upregulated (see Supplementary Information for all array results). The genes were sorted on fold change and the top 20 differentially regulated genes are shown in Figure 3a . In order to gain more insight into the function of differentially expressed genes, pathway analysis was performed on the whole genomewide data set by Gene Set Enrichment Analysis, provided by the Broad Institute (Cambridge, MA, USA), using false discovery rate qvalue of o0.005. This analysis of macrophages treated with T. suis SPs and LPS versus treatment with LPS alone resulted in 13 significantly downregulated pathways and 6 pathways significantly upregulated by T. suis SPs ( Table 1) . Most of the pathways downregulated by T. suis SPs are pathways that are associated with a pro-inflammatory function, namely the inflammatory pathway, cytokine pathway, DC pathway, IL-23 pathway, TLR Figure 1 . T. suis SPs reduce TNF-a secretion from different TLR4-activated human macrophage subsets. Monocytes were differentiated into macrophages using NHS, GM-CSF or M-CSF and subsequently stimulated with LPS (100 ng ml À 1 ), T. suis SPs (40 or 80 mg ml À 1 ) or both. After incubation for 24 h, TNF-a secretion was determined in the supernatants using ELISA. Experiments were performed in triplicate using monocyte-derived macrophages from three different blood donors. *Pp0.05 and **Pp0.01. signalling pathway, local acute inflammatory response pathway and the IL-27 pathway. In addition, the cytosolic DNA sensing pathway and the RIG-I-like receptor signalling pathway, also downregulated by T. suis SPs, also play a role in innate immune activation 20 and are considered pro-inflammatory. Among the pathways upregulated by treatment of the macrophages with T. suis SPs and LPS, versus LPS alone, is the CXCR4 pathway that is involved in the recruitment and migration of immune cells upon ligation with its ligand CXCL12. 21 The other pathways upregulated by T. suis SPs play a role in cellular signalling, cell growth or the citric acid cycle.
Differential gene expression in T. suis SP-treated versus untreated macrophages Analysis of untreated GM-CSF-differentiated macrophages compared with macrophages stimulated with T. suis SPs revealed a group of 752 differentially expressed genes (Po0.05). The helminth T. suis is a pathogen, and might induce pro-inflammatory responses (similar to LPS) on its own. Here, we are mainly interested in the potential of T. suis SPs to suppress TLR4-induced responses, and we focussed on the effects of T. suis SPs on GM-CSF-differentiated macrophages that are opposite to the effects of LPS. This resulted in 83 genes that were significantly upregulated by T. suis SPs and 26 genes that were downregulated by T. suis SPs, of which the top 20 genes (sorted on fold change) are shown ( Figure 3b ).
Real-time PCR validation
To validate the results of the gene array, quantitative real-time PCR was performed on a total of 16 selected genes, comprising 9 differentially expressed genes in the T. suis SPs þ LPS vs the LPS gene set and 7 genes of the T. suis SPs versus unstimulated gene set. Interestingly, the majority of these genes, including the LPSinduced transcripts of BATF3, CCL1, CXCL9, IL-12B, NR1H3, P2RX7 and PTRF, were significantly downregulated by T. suis SPs (Figure 4a ), confirming the gene array results. In addition, mRNA expression levels of ID3, RGS2 and THBS1 were significantly induced after T. suis SP stimulation, whereas CXCR4 and TLR7 were also induced although not significantly ( Figure 4b ). Gene functions of the validated genes according to Source, Stanford (http:// puma.princeton.edu/cgi-bin/source/sourceResult), are shown in Table 2 .
T. suis SPs have a less potent effect on GM-CSF-differentiated macrophages stimulated with TLR2 or -3 agonist To define whether the effects of T. suis SPs induced in macrophages stimulated with TLR4 ligand LPS can also be found through other TLR pathways, GM-CSF-differentiated macrophages were stimulated with Pam3CSK4 (TLR2 ligand) or polyinosinicpolycytidylic acid (polyI:C; TLR3 ligand). Subsequently, mRNA levels of BATF3, CCL1, CXCL9, EDN1, IL12B, IRF8, NR1H3, P2RX7 and PTRF were determined. In TLR2-or TLR3-stimulated macrophages, T. suis SPs suppressed TLR-induced CCL1 expression in a similar manner as in TLR4-stimulated macrophages (Figures 5a-i ). In addition, upon stimulation with Pam3CSK4, the effects of T. suis SPs on EDN1 expression were similar to T. suis SP effects on TLR4 stimulation, and EDN1 was significantly downregulated by T. suis SPs in polyI:C-stimulated macrophages. Expression of NR1H3 and BATF3 were unaffected by T. suis SPs in both TLR2-and TLR3-stimulated macrophages. Furthermore, our data indicate that both the TLR2-and TLR3-induced TNFa secretion were significantly inhibited by T. suis SPs, in contrast to IL-6 secretion that is unaffected (Figures 5j-k) . However, the effects found in TLR2-or TLR3-stimulated macrophages are less robust compared with the effects induced in TLR4-stimulated macrophages, indicating that T. suis SPs predominantly interfere with TLR4-mediated signalling.
T. suis SPs downregulate the expression and function of P2RX7 P2RX7 is a purinergic receptor belonging to the family of ATPsensitive ionotropic receptors mostly expressed on immune cells, like lymphocytes, macrophages and dendritic cells. 22 Upon stimulation with ATP a reversible channel is formed, eventually leading to the maturation and release of the pro-inflammatory cytokine IL-1b, a multipotential inflammatory mediator produced in abundance by activated monocytes and macrophages contributing to an inflammatory state. 22 As shown in Figure 4a , P2RX7 is downregulated by T. suis SPs on mRNA level, validating the results from the gene array. DC treatment with T. suis SPs results in a suppression of P2RX7 (Figure 6a ) as well. In addition, NHS and M-CSF-differentiated macrophages downregulate P2RX7 in response to T. suis SPs (Figures 6b and c) , indicating that the observed effects are found in different innate immune cells. As addition of ATP to macrophages has been described to result in ) or both for 6 h and (a) TNF-a, (b) IL-6 and (c) IL-10 cytokine levels were measured in the culture supernatants using a multiplex bead assay. Results are depicted relative to the values for LPS-induced secretion, and 100% corresponds to 21.8 ± 3.2 ng ml À 1 for TNF-a, 35.9 ± 3.1 ng ml À 1 for IL-6 and 47.0 ± 6.1 pg ml À 1 for IL-10. Experiments were performed in triplicate using monocyte-derived macrophages from three different blood donors. **Pp0.01 and ***Pp0.001.
P2RX7-dependent IL-1b secretion into the culture medium, this allows us to use IL-1b secretion as a read-out for the presence of P2RX7 in GM-CSF-differentiated macrophages. Notably, macrophages that are co-incubated with LPS and T. suis SPs secrete significantly lower levels of IL-1b compared with LPS-induced IL-1b-secretion ( Figure 7) . Thus, the T. suis SP-induced reduction of LPS-induced IL-1b secretion shows at a functional level that T. suis SPs contribute to a reduced inflammatory state of human macrophages.
DISCUSSION
Recent clinical trials in patients with inflammatory diseases like MS and IBD have shown the beneficial effects of helminth therapy, 4, 10 but to date, the underlying mechanism of action remains largely unknown. To explore possible mechanisms by which T. suis could modulate the immune system, we focussed in the current study on human macrophages that are crucial innate immune players in MS and IBD pathogenesis. We here show that soluble products of the helminth T. suis are able to reduce a broad range of inflammatory responses in macrophages, thereby providing further mechanistic insight into its therapeutic potential for patients with inflammatory diseases.
Gut epithelial cells are the first cells to come in contact with helminths and we have recently shown that T. suis products reduce the barrier function of epithelial cells. 23 As a result, T. suis products can reach the underlying lamina propria, where they encounter resident macrophages. In general, these gut Helminths are known to counteract these inflammatory T responses, 25 possibly via its interaction with gut-resident macrophages. In general, macrophages are highly heterogenic and several methods are used to obtain different macrophage subsets. 13, 26 We here show that regardless of the culturing method (using NHS, GM-CSF or M-CSF), TLR4 triggering results in high TNF-a production that is strongly reduced by T. suis SPs. In this study, we focussed on GM-CSF-activated macrophages, as GM-CSF plays a crucial pathogenic role during inflammation where it is produced by T cells. 18 GM-CSF-deficient mice are resistant to experimental autoimmune encephalomyelitis and are particularly unable to sustain immune cell infiltration into the central nervous system (CNS), and mice treated with anti-GM-CSF after disease onset recovered completely. 19 Here we show that T. suis SPs skew inflammatory GM-CSF differentiated macrophages into a more anti-inflammatory state. Remarkably, the TLR4-induced expression and production levels of the pro-inflammatory cytokines TNF-a and IL-6 were almost completely inhibited by T. suis SPs, whereas secretion of the antiinflammatory cytokine IL-10 was enhanced, indicating a potent anti-inflammatory effect. Analysis of the effects of T. suis SPs on gene expression profiles of GM-CSF-differentiated macrophages, with and without TLR4 activation, and the concurrent pathway analysis, revealed a strong inhibition of several pro-inflammatory pathways. The TLR4-induced genes that are downregulated by T. suis SPs include several genes with a pro-inflammatory function that are relevant in inflammatory diseases, such as IL-12B, CCL1, CXCL9, P2RX7 and EDN1. In particular, IL-12B is significantly increased in MS patients who show gadolinium-enhanced plaques on magnetic resonance imaging. 27 IL-12B is likely to play a role in the pathogenesis of both MS and IBD as it drives the differentiation of naive T cells to pro-inflammatory T cells that subsequently results in enhanced T-cell migration into the CNS by upregulation of adhesion molecules and/or enhanced T helper cell type 1 and type 17 responses in the gut. 28 Moreover, EDN1 is also known as a potent pro-inflammatory molecule and has a pathogenic role in the development of experimental autoimmune encephalomyelitis. 29 Next to that, EDN1 is reported to induce an upregulation of TNF-a, IL-1b, IL-6 and GM-CSF in human monocytes. 30 The pathway analysis also shows that T. suis SPs have a direct effect on GM-CSF-differentiated macrophages, for example, by upregulation of the CXCR4 pathway. It has been shown that ubiquitin, a CXCR4 ligand, is able to suppress immune responses by inhibiting LPS-stimulated TNF-a production and upregulates the production of IL-4, IL-10 and IL-13. 31 Interestingly, the secretion of the anti-inflammatory cytokine IL-10 was significantly enhanced by T. suis SPs in the presence of LPS compared with LPS alone. In conclusion, these results clearly indicate the anti-inflammatory effect of T. suis SPs on the immune activity of human macrophages.
The T. suis SP-dependent downregulation of P2RX7 resulted in a significantly reduced secretion of IL-1b in TLR4-activated human macrophages upon binding of the P2RX7 ligand benzoylbenzoyl ATP. Enhanced levels of P2RX7 associated with the production of pro-inflammatory cytokines in IBD are shown in intestinal epithelial cells, another type of innate immune cell carrying TLR4, during polymorphonuclear leukocyte transepithelial migration. In addition, epithelial P2RX7 activation is required for the production of IL-1b. 32 In case of MS, It was shown that P2RX7 is upregulated on activated macrophages/microglial cells 33 and that IL-1b is mainly produced by monocytes and macrophages. The downregulation of IL-1b is relevant in the pathogenesis of MS as IL-1b levels are elevated in both the sera and the CSF of MS patients. 34 In particular, interaction with IL-1b causes astrocytes to upregulate P2RX7 themselves and induces the secretion of several cytokines and chemokines, causing a further increase of mononuclear cells into the CNS. 35, 36 Within the body, ATP can be released in an autocrine manner when cells are challenged by inflammatory initiators or by cells undergoing apoptosis or necrosis in neurodegenerative and neuroinflammatory conditions; 33 therefore, the oligodendrocyte cell death induced by IL-1b causes more ATP to be released and may thus further activate the P2RX7/IL-1b-loop. Consequently, specific intervention by T. suis SPs in this pathway may therefore be beneficial in the treatment of inflammatory diseases at various levels.
We here show that the observed effects of T. suis SPs on dampening of the inflammatory response in human macrophages is largely mediated by TLR4, but similar observations were done by TLR2 or TLR3 activation, although to a lesser extent. As TLR4 shares ) or both for different time points (2 or 6 h) and mRNA levels for (a) BATF3, CCL1, CXCL9, EDN1, IRF8, IL-12b, NR1H3 P2RX7 and PTRF or (b) CXCR4, ID3, Gal9, RGS2, TGFb, THBS1 and TLR7 were determined using quantitative real-time PCR and presented as relative expression compared with GAPDH. Experiments were performed in triplicate using monocyte-derived macrophages from three different blood donors and the highest Ct value was set as 100% for each donor separately, after which the results from the different donors were combined. *Pp0.05, **Pp0.01 and ***Pp0.001. pathway. Among the genes tested, CCL1 and EDN1 are the only genes that are also downregulated by T. suis SPs after TLR2 and TLR3 stimulation, but to date, their regulation is largely unknown. TNF-a secretion was shown to be significantly reduced after TLR2 and TLR3 activation upon T. suis SP treatment, whereas secretion of IL-6 was not suppressed, suggesting different regulatory mechanisms. Indeed, differential regulation of TNF-a and IL-6 was previously shown to be regulated by A2-and A3-adenosine receptors. 37 We have demonstrated before that T. suis SPs bind C-type lectin receptors 16 on DCs, and it has previously been shown that TLR-induced signalling in alveolar macrophages can be modulated through C-type lectin receptor ligation. 38 It is possible that T. suis SPs inhibit TLR4 signalling in human macrophages in a similar manner, although further research is required to confirm this hypothesis.
From epidemiological, observational and, more recently, phase I clinical trials, it appears that helminths have beneficial effects on IBD and MS patients; however, for MS the mechanistic correlation between gut infections and a CNS disease is unclear. Recently, Fleming 39 postulated the hypothesis that helminths in the gut might set a systemic immune 'milieu' by influencing the large population of immune cells in the gut. Another possibility is that SPs from the helminths reach the blood circulation and influence circulating immune cells like monocytes before they enter the CNS and thus in advance modulate their immune response. Helminths might also affect perivascular macrophages that have been shown to play an important role in CNS autoimmunity. 40 In conclusion, we here show that SPs from the helminth T. suis suppress the expression of a broad range of TLR4-induced proinflammatory genes and proteins as well as inflammatory pathways in GM-CSF macrophages. Among these genes are IL-12B and P2RX7, both of which are significantly altered in inflammatory diseases like MS and IBD. 27, 33 Consequently, we here provide mechanistic insights into the effects of T. suis SPs on the immune system and in particular macrophages, highlighting its putative therapeutic value for the treatment of inflammatory diseases.
MATERIALS AND METHODS Reagents
CD14 microbeads were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), Dulbecco's modified Eagle's medium (Gibco) from Life Technologies (Paisley, UK) and fetal calf serum from Lonza (Basel, Switzerland). Recombinant human TNF-a, glutamine, penicillin and streptomycin were from Invitrogen (Carlsbad, CA, USA). GM-CSF (Immunotools, Friesoythe, Germany), M-CSF (Immunotools) and NHS (Bio Whittaker, Walkersville, MD, USA) were used for maturation of monocytes into macrophages. Escherichia coli LPS (batch 026:B6) and PolyI:C were purchased from Sigma (St Louis, MO, USA) and Pam3CSK 4 from Invivogen (Carlsbad, CA, USA). Benzoylbenzoyl ATP and Lidocaine were used from Sigma-Aldrich (Munich, Germany).
Preparation of T. suis SPs
As described previously, 16 T. suis-infected pigs were killed and worms were collected from the colon and the caecum. The worms were washed extensively with 0.98% NaCl and frozen in liquid nitrogen. In order to prepare SPs, the frozen worms were crushed using mortar and pestle and dissolved in MilliQ (Millipore, Amsterdam, The Netherlands). To remove insoluble material the solution was centrifuged at 10 000 g (4 1C) for 30 min. The supernatant was filtered (0.45 mm) and kept at À 80 1C until use. T. suis SPs were tested in the presence of polymyxin B (Applichem, Darmstadt, Germany) to block LPS activity. No effect of polymyxin B addition was observed in our in vitro assays, excluding significant LPS contamination of T. suis SPs.
Monocyte isolation, cell culture and experimental setup Buffy coats of healthy blood donors were supplied by Sanquin (Amsterdam, The Netherlands). Human peripheral blood mononuclear cells were isolated from buffy coats by Ficoll gradient as previously described. 16 Monocytes were isolated from the peripheral blood mononuclear cells using CD14 magnetic microbeads. For maturation into macrophages, cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1% glutamate, 1% penicillin and 1% streptomycin. In addition, 50 ng ml À 1 GM-CSF, 25 ng ml À 1 M-CSF or 5% (v/v) NHS was added. After 6 days of culture at 37 1C, the macrophages were harvested, replated and incubated with or without T. suis SPs (40 mg ml À 1 , unless otherwise indicated) for 15 min, followed by either addition of LPS (100 ng ml À 1 ), polyI:C (25 mg ml
) or PAM3CSK4 (5 mg ml À 1 ) and incubation for indicated time periods (2 or 6 h). For DC differentiation, cells were cultured for 4 days in RPMI containing 10% fetal calf serum, 1% glutamate, 1% penicillin, 1% streptomycin, 250 IU ml Abbreviations: ATP, adenosine triphosphate; BATF3, basic leucine zipper transcription factor, ATF-like 3; CCL1, chemokine C-C motif ligand 1; CXCL9, chemokine C-X-C motif ligand 9; CXCR4, chemokine C-X-C motif receptor 4; EDN1, endothelin-1; Gal9, Galectin-9; ID3, inhibitor of DNA binding 3; IL-12B, interleukin 12 p40; IRF8, interferon regulatory factor 8; NR1H3, nuclear receptor subfamily 1, group H, member 3; P2RX7, purinergic receptor P2X; PTRF, polymerase I and transcription release factor; RGS2, regulator of G-protein signalling 2; TGFb, transforming growth factor-b; THBS1, thrombospondin 1; TLR7, Toll-like receptor 7.
The helminth Trichuris suis dampens innate immune responses MK Ottow et al Figure 5 . Effect of T. suis SPs on TLR-induced response in human GM-CSF macrophages. GM-CSF macrophages were incubated with either T. suis SPs (40 mg ml ) or both T. suis SPs þ TLR ligand for different time periods (2 or 6 h). mRNA levels for (a) BATF3, (b) CCL1, (c) CXCL9, (d) EDN1, (e) IL-12b, (f ) IRF8, (g) NR1H3, (h) P2RX7 and (i) PTRF were determined using quantitative real-time PCR and presented as relative expression compared with GAPDH. The highest Ct value was set as 100% for each donor separately, after which the results from the different donors were combined. Cytokine secretion levels for (j) TNF-a and (k) IL-6 of TLR2 (left) or TLR3 (right) ligand-stimulated human GM-CSF macrophages were determined. Values are depicted as percentages compared with LPS-induced secretion and 100% corresponds to 8.7±0.6 ng ml À 1 (TLR2) and 9.9±0.2 ng ml À 1 (TLR3) for TNF-a, and 204.2±74.9 ng ml À 1 (TLR2) and 146.9±12.5 ng ml À 1 (TLR3) for IL-6. Experiments were performed in triplicate using monocyte-derived macrophages from three different blood donors. *Pp0.05, **Pp0.01 and ***Pp0.001.
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Gene expression analysis by microarray
After 6 h of incubation, GM-CSF-differentiated macrophages from three different donors treated with T. suis SPs for 15 min and subsequently activated with LPS (100 ng ml
), were harvested and snap-frozen at À 80 1C. Total RNA was isolated using RNeasy spin columns (Qiagen, Venlo, The Netherlands). As previously described, 41 RNA of the samples was amplified and biotinylated using the Illumina TotalPrep RNA amplification Kit (Ambion, Austin, TX, USA). The samples, having passed quality control, were hybridized to Sentrix HumanHT-12v4 Expression BeadChip arrays (Illumina, San Diego, CA, USA), followed by scanning and feature extraction, all performed at ServiceXS (Leiden, The Netherlands). Bead summary intensities were log2-transformed and normalized using quantile normalization. 41 For identification of differentially expressed genes between the four groups (control, T. suis SPs, LPS and LPS þ T. suis SPs), we used Bayes-regularized one-way analysis of variance, developed for microarray data with multiple conditions, with additional Tukey's HSD (honest significant difference) post hoc multiple comparisons test to determine which pairs of groups showed differential expression, 41 applying a P-value of 0.05. Pathway-level analysis of gene expression data was performed by gene set enrichment analysis, using gene set permutation of C2v3.1 canonical pathways. 42 Quantitative real-time PCR GM-CSF-differentiated macrophages, treated with T. suis SPs and/or LPS for 2 and 6 h, were harvested and snap-frozen at À 80 1C. mRNA was isolated using an mRNA Capture kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol. The Reverse Transcription System kit (Promega, Madison, WI, USA) was used for cDNA synthesis according to the manufacturer's protocol. Oligonucleotide primers as shown in Table 3 were designed using Primer Express 2.0 (Applied Biosystems, Bedford, MA, USA) and synthesized by Invitrogen (USA). TLR7 primers were kindly provided by Dr JJ Garcia Vallejo (VU University Medical Center, Amsterdam, The Netherlands). Real-time PCR reactions were performed with the SYBR Green method as described previously. 43 Functional ATP Assay GM-CSF-activated macrophages were cultured for 48 h with LPS and/or T. suis SPs. Subsequently, cells were harvested, replated and filtered (0.45 mm), benzoylbenzoyl ATP (300 mM) was added for 30 min, after which the supernatant was collected and frozen at À 20 1C until IL-1b determination by ELISA.
Statistical analysis
Results are expressed as the mean ± s.e.m. Statistical analyses were performed using SPSS 20 software (IBM, New York, NY, USA). All data Figure 6 . P2RX7 expression levels in DCs, NHS and M-CSF macrophages. P2RX7 mRNA levels were determined using real-time quantitative PCR and presented as relative expression compared with GAPDH in (a) monocyte-derived dendritic cells after incubation with either T. suis SPs (40 mg ml À 1 ), LPS (10 ng ml ) or both for different time periods (2 or 6 h). Experiments were performed using monocyte-derived macrophages from three different blood donors and the highest Ct value (2 h LPS) was set as 100% for each donor separately, after which the results from the different donors were combined. *Pp0.05, **Pp0.01 and ***Pp0.001. ) or both in the presence or absence of benzoylbenzoyl ATP (BzATP; 300 mM). Results are depicted relative to the value for ATP-induced secretion of IL-1b that was set at 100% and corresponded to 29.3±8.5 pg ml À 1 . Experiments were performed in triplicate using monocyte-derived macrophages from three different blood donors. ***Pp0.001. Abbreviations: BATF3, basic leucine zipper transcription factor, ATF-like 3; CCL1, chemokine C-C motif ligand 1; CXCL9, chemokine C-X-C motif ligand 9; CXCR4, chemokine C-X-C motif receptor 4; EDN1, endothelin-1; Gal9, Galectin-9; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ID3, inhibitor of DNA binding 3; IL-12B, interleukin 12 p40; IRF8, interferon regulatory factor 8; NR1H3, nuclear receptor subfamily 1, group H, member 3; P2RX7, purinergic receptor P2X; PTRF, polymerase I and transcription release factor; RGS2, regulator of G-protein signalling 2; TGFb, transforming growth factor-b; THBS1, thrombospondin 1.
